Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.
Insider and Institutional Ownership
95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Enliven Therapeutics has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.25, suggesting that its share price is 525% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Enliven Therapeutics | N/A | -21.04% | -20.41% |
| Vivos Therapeutics | -127.70% | -2,325.64% | -98.12% |
Earnings & Valuation
This table compares Enliven Therapeutics and Vivos Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enliven Therapeutics | N/A | N/A | -$103.69 million | ($1.67) | -23.69 |
| Vivos Therapeutics | $19.57 million | 0.50 | -$21.17 million | ($2.14) | -0.33 |
Vivos Therapeutics has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Enliven Therapeutics and Vivos Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enliven Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
Enliven Therapeutics currently has a consensus price target of $58.40, suggesting a potential upside of 47.59%. Vivos Therapeutics has a consensus price target of $2.75, suggesting a potential upside of 292.86%. Given Vivos Therapeutics’ higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Enliven Therapeutics.
Summary
Enliven Therapeutics beats Vivos Therapeutics on 9 of the 14 factors compared between the two stocks.
About Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
